OBJECTIVE: Somatostatin is a neuropeptide with modulatory effects on the immune system and the function of synovial cells; it has antiangiogenic and antiproliferative properties. This study aimed to evaluate the clinical, histological, and articular tissue cytokine mRNA response to somostatin treatment in rat adjuvant-induced arthritis (AIA). METHODS: Adjuvant-induced arthritis was induced in a total of 68 Lewis rats by immunization with complete Freund's adjuvant. Twenty-four rats were treated with a long-acting somostatin analogue 14 days after disease induction. Twenty-four untreated rats served as controls. The severity of arthritis was scored weekly for 42 days. In a second experiment, 20 rats (ten treated, ten controls) were killed 21 days after treatment for assessment of joint histopathology and articular tissue cytokine mRNA expression. RESULTS: Somatostatin analogue treatment significantly reduced histological scores of early inflammatory changes and increased articular tissue mRNA expression of interleukin-1 beta (IL-1beta). A trend toward improvement in physical scores of joint inflammation was seen in the treated group. Late destructive changes were not significantly different. CONCLUSION: Treatment with a somostatin analogue attenuated early inflammatory changes in AIA joints and increased mRNA expression of IL-1beta in the articular tissues of rats with ongoing arthritis. Improvement in the physical findings of joint inflammation was mild.
OBJECTIVE:Somatostatin is a neuropeptide with modulatory effects on the immune system and the function of synovial cells; it has antiangiogenic and antiproliferative properties. This study aimed to evaluate the clinical, histological, and articular tissue cytokine mRNA response to somostatin treatment in rat adjuvant-induced arthritis (AIA). METHODS: Adjuvant-induced arthritis was induced in a total of 68 Lewis rats by immunization with complete Freund's adjuvant. Twenty-four rats were treated with a long-acting somostatin analogue 14 days after disease induction. Twenty-four untreated rats served as controls. The severity of arthritis was scored weekly for 42 days. In a second experiment, 20 rats (ten treated, ten controls) were killed 21 days after treatment for assessment of joint histopathology and articular tissue cytokine mRNA expression. RESULTS:Somatostatin analogue treatment significantly reduced histological scores of early inflammatory changes and increased articular tissue mRNA expression of interleukin-1 beta (IL-1beta). A trend toward improvement in physical scores of joint inflammation was seen in the treated group. Late destructive changes were not significantly different. CONCLUSION: Treatment with a somostatin analogue attenuated early inflammatory changes in AIA joints and increased mRNA expression of IL-1beta in the articular tissues of rats with ongoing arthritis. Improvement in the physical findings of joint inflammation was mild.
Authors: A M ten Bokum; E G Lichtenauer-Kaligis; M J Melief; P M van Koetsveld; C Bruns; P M van Hagen; L J Hofland; S W Lamberts; M P Hazenberg Journal: J Endocrinol Date: 1999-04 Impact factor: 4.286
Authors: M Matucci-Cerinic; F Borrelli; S Generini; A Cantelmo; I Marcucci; F Martelli; P Romagnoli; S Bacci; A Conz; P Marinelli Journal: Arthritis Rheum Date: 1995-11
Authors: Mitra Khumbatta; Bahrom Firozgary; David John Tweardy; Joel Weinstock; Gohar Firozgary; Zal Bhatena; Tushar Bulsara; Ricardo Siller; Prema Robinson Journal: Biomed Res Int Date: 2014-07-09 Impact factor: 3.411
Authors: Li Li; Rong Luo; Yuan Guo; Fanrong Yao; Dongyuan Cao; Shaojie Ma; Jun Wang; Huisheng Wang; Yan Zhao Journal: Biomed Res Int Date: 2014-05-07 Impact factor: 3.411